These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32005552)

  • 21. Vesical Imaging-Reporting and Data System (VI-RADS®): Initial experience in the classification of muscle-invasive bladder cancer.
    Etxano J; Rodríguez-Vigil B; Pérez F; Beardo P; Viguri A; Tolosa E; Martínez de Guereñu B
    Actas Urol Esp (Engl Ed); 2021 May; 45(4):320-325. PubMed ID: 33531283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 2021;4:12-9.
    Montorsi F; Bandini M; Moschini M; Dehò F; Gallina A
    Eur Urol Oncol; 2021 Feb; 4(1):126. PubMed ID: 33309069
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol 2023;6:508-15.
    D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
    Eur Urol Oncol; 2024 Jun; 7(3):639-640. PubMed ID: 37978025
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol 2015;68:86-94; Re: Matthew Bultitude, Ben Challacombe. Simple Prostatectomy: A Step Too Far for Laparoscopy? Eur Urol 2015;68:95-6. Eur Urol 2015;68:e7-8.
    Autorino R; Zargar H; Porpiglia F
    Eur Urol; 2015 Jul; 68(1):e9-10. PubMed ID: 25666848
    [No Abstract]   [Full Text] [Related]  

  • 25. Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Thoeny HC; Bellin MF; Comperat EM; Thalmann GN
    Eur Urol; 2018 Sep; 74(3):307-308. PubMed ID: 29960749
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43.
    Bandini M; Necchi A
    Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
    Heer R; Tan WS; Gravestock P; Vadiveloo T; Lewis R; Penegar S; Vale L; MacLennan G; Hall E;
    Eur Urol; 2024 Mar; 85(3):309-312. PubMed ID: 37330372
    [No Abstract]   [Full Text] [Related]  

  • 28. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion.
    Wang H; Luo C; Zhang F; Guan J; Li S; Yao H; Chen J; Luo J; Chen L; Guo Y
    Radiology; 2019 Jun; 291(3):668-674. PubMed ID: 31012814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy of retrospective application of the Vesical Imaging-Reporting and Data System: preliminary results.
    Vaz A; Zaparolli M
    Radiol Bras; 2020; 53(1):21-26. PubMed ID: 32313332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer.
    Wang Z; Shang Y; Luan T; Duan Y; Wang J; Wang H; Hao J
    Cancer Imaging; 2020 Apr; 20(1):26. PubMed ID: 32252816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghøj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthøj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol 2023;83:125-30.
    Pedersen GL; Mogensen K; Rosthøj S; Hermann GG
    Eur Urol; 2023 Dec; 84(6):e154. PubMed ID: 37500341
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
    Groenendijk FH; Fransen van de Putte EE; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2015 Aug; 68(2):e33-4. PubMed ID: 25776733
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:329-40.
    Rosenkrantz AB; Turkbey B; Barentsz J; Weinreb JC
    Eur Urol; 2019 Sep; 76(3):e79. PubMed ID: 31182228
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11.
    Gschwend JE; Heck M
    Eur Urol; 2019 Aug; 76(2):e37. PubMed ID: 31056229
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.
    Giacalone NJ; Niemierko A; Shipley WU; Efstathiou JA
    Eur Urol; 2017 Sep; 72(3):e64-e65. PubMed ID: 28642020
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply to Per-Uno Malmström and Bruce J. Trock's Letter to the Editor re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.050.
    Sylvester R
    Eur Urol; 2016 Jan; 69(1):e12-3. PubMed ID: 26215601
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Hussain SA; Porta N; Hall E; Qureshi M; Lewis R; Huddart R; James ND
    Eur Urol; 2021 Aug; 80(2):e51-e52. PubMed ID: 34053780
    [No Abstract]   [Full Text] [Related]  

  • 38. Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Arends TJH; Witjes JA
    Eur Urol; 2019 Feb; 75(2):e26. PubMed ID: 30268661
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Ben J. Challacombe, Bernard H. Bochner, Prokar Dasgupta, et al. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 2011;60:767-75.
    Simonato A; Ennas M
    Eur Urol; 2012 Apr; 61(4):e29; author reply e30. PubMed ID: 22206801
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply from authors re: Marko Babjuk. Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives. Eur Urol 2010;58:191-2 and Giacomo Novara, Vincenzo Ficarra. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010;58:193-4.
    Divrik RT; Sahin AF; Ergör G
    Eur Urol; 2010 Aug; 58(2):195-6. PubMed ID: 20471156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.